Hypogonadism screening: Difference between revisions

Jump to navigation Jump to search
 
(4 intermediate revisions by 2 users not shown)
Line 4: Line 4:


==Overview==
==Overview==
According to the endocrine society, screening for hypogonadism is recommended. Hypogonadism screening is important in order to diagnose the disease early and provide the appropriate treatment. The endocrine society recommended screening for men patients who present with [[erectile dysfunction]], [[infertility]], [[HIV]] patients and young patients with [[Osteoporosis (patient information)|osteoporosis]].  
According to the endocrine society, screening for hypogonadism is not recommended as it is not cost-effective. Hypogonadism screening may be done in order to diagnose the disease early and provide the appropriate treatment. Screening may be done for men who present with [[erectile dysfunction]], [[infertility]], [[HIV]], and young patients with [[Osteoporosis (patient information)|osteoporosis]].  


==Screening==
==Screening==
Screening for hypogonadism is not recommended by the endocrine society as it costs a lot. However, it may be performed in men who are thought to be at high risk of having hypogonadism. Screening is performed in men showing the following:<ref name="pmid27132573">{{cite journal| author=Ross A, Bhasin S| title=Hypogonadism: Its Prevalence and Diagnosis. | journal=Urol Clin North Am | year= 2016 | volume= 43 | issue= 2 | pages= 163-76 | pmid=27132573 | doi=10.1016/j.ucl.2016.01.002 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=27132573  }} </ref><ref name="pmid20525905">{{cite journal| author=Bhasin S, Cunningham GR, Hayes FJ, Matsumoto AM, Snyder PJ, Swerdloff RS et al.| title=Testosterone therapy in men with androgen deficiency syndromes: an Endocrine Society clinical practice guideline. | journal=J Clin Endocrinol Metab | year= 2010 | volume= 95 | issue= 6 | pages= 2536-59 | pmid=20525905 | doi=10.1210/jc.2009-2354 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=20525905  }}</ref>
Screening for hypogonadism is not recommended by the endocrine society as it is not cost-effective. However, it may be performed in men who are thought to be at high risk of having hypogonadism. Screening is performed in men showing the following:<ref name="pmid27132573">{{cite journal| author=Ross A, Bhasin S| title=Hypogonadism: Its Prevalence and Diagnosis. | journal=Urol Clin North Am | year= 2016 | volume= 43 | issue= 2 | pages= 163-76 | pmid=27132573 | doi=10.1016/j.ucl.2016.01.002 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=27132573  }} </ref><ref name="pmid20525905">{{cite journal| author=Bhasin S, Cunningham GR, Hayes FJ, Matsumoto AM, Snyder PJ, Swerdloff RS et al.| title=Testosterone therapy in men with androgen deficiency syndromes: an Endocrine Society clinical practice guideline. | journal=J Clin Endocrinol Metab | year= 2010 | volume= 95 | issue= 6 | pages= 2536-59 | pmid=20525905 | doi=10.1210/jc.2009-2354 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=20525905  }}</ref>
*[[Erectile dysfunction]]  
*[[Erectile dysfunction]]  
*[[Infertility]]
*[[Infertility]]
*[[HIV]] infected individuals  
*[[HIV]] infected individuals  
*Men who got exposed to [[radiation]] on the [[brain]]  
*Patients with previous exposure to [[radiation]] on the [[brain]]  
*Young patients with [[osteoporosis]].
*Young patients with [[osteoporosis]].


==References==  
==References==  
{{Reflist|2}}
{{Reflist|2}}

Latest revision as of 20:43, 3 October 2017

Hypogonadism Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Hypogonadism from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

X ray

CT

MRI

Echocardiography or Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Hypogonadism screening On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Hypogonadism screening

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Hypogonadism screening

CDC on Hypogonadism screening

Hypogonadism screening in the news

Blogs on Hypogonadism screening

Directions to Hospitals Treating Hypogonadism

Risk calculators and risk factors for Hypogonadism screening

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Ahmed Elsaiey, MBBCH [2]

Overview

According to the endocrine society, screening for hypogonadism is not recommended as it is not cost-effective. Hypogonadism screening may be done in order to diagnose the disease early and provide the appropriate treatment. Screening may be done for men who present with erectile dysfunction, infertility, HIV, and young patients with osteoporosis.

Screening

Screening for hypogonadism is not recommended by the endocrine society as it is not cost-effective. However, it may be performed in men who are thought to be at high risk of having hypogonadism. Screening is performed in men showing the following:[1][2]

References

  1. Ross A, Bhasin S (2016). "Hypogonadism: Its Prevalence and Diagnosis". Urol Clin North Am. 43 (2): 163–76. doi:10.1016/j.ucl.2016.01.002. PMID 27132573.
  2. Bhasin S, Cunningham GR, Hayes FJ, Matsumoto AM, Snyder PJ, Swerdloff RS; et al. (2010). "Testosterone therapy in men with androgen deficiency syndromes: an Endocrine Society clinical practice guideline". J Clin Endocrinol Metab. 95 (6): 2536–59. doi:10.1210/jc.2009-2354. PMID 20525905.